Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.

Autor:	Labelle, Alain, Boulay, Luc Jean, Lapierre, Yvon Denis, Labelle, A, Boulay, L J, Lapierre, Y D
Předmět:	PLACEBOS SCHIZOPHRENIA DRUG therapy for schizophrenia DIAGNOSIS of schizophrenia ANTIPSYCHOTIC agents BENZAMIDE BENZODIAZEPINES CLINICAL trials COMPARATIVE studies DOSE-effect relationship in pharmacology RESEARCH methodology MEDICAL cooperation MEMORY RESEARCH RISPERIDONE TIME EVALUATION research TRANQUILIZING drugs RANDOMIZED controlled trials BLIND experiment RETROSPECTIVE studies PHARMACODYNAMICS THERAPEUTICS
Zdroj:	Canadian Journal of Psychiatry; Nov1999, Vol. 44 Issue 9, p887-892, 6p, 1 Diagram, 5 Charts
Abstrakt:	Objective: To determine if the inclusion of a placebo control in clinical trials of schizophrenia affects retention rates in the first 35 days of inclusion relative to trials that did not have a placebo control. Method: This was a retrospective study of 8 double-blind clinical trials, 5 of which had a placebo control while 3 did not. Using survival analysis, retention rates between the placebo-controlled trials (PCTs) and the nonplacebo-controlled trials (NPCTs) were compared. Screening and percentage improvement on Brief Psychiatric Rating Scale and Positive and Negative Syndrome Scale scores were compared. Results: Significantly more patients were retained in the 35-day period for NPCTs. Also, the PCT group had significantly more psychopathology at screening than did the NPCT group. Conclusions: Differences in retention rates between PCTs and NPCTs cannot be uniquely attributed to placebo itself. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu